Ammonia Anhydrous CAS: 7664-41-7
Related Insights
PVC Supply Chain Risk: How Disruptions at a Major Gulf Petrochemical Hub Could Reshape Global Procurement
PVC buyers increasingly face supply chain risks that extend beyond simple price fluctuations. This analysis examines how prolonged disruptions at a major Gulf petrochemical hub could influence global PVC availability, sourcing strategies and procurement decisions over the coming years.
Using the Kiel Institute to Separate Temporary Hormuz Costs from Permanent Chemical Procurement Shifts
After the Hormuz shutdown, chemical buyers face a mix of temporary price spikes and lasting market shifts. This article applies the Kiel Institute framework to isolate recoverable costs from permanent baseline changes, providing a roadmap for data‑driven contract renegotiations. Implementing these insights helps teams win back margins as conditions normalize.
Jordan API Supply: Post-Crisis Recovery Assessment for Antibiotic Procurement Teams
Jordan's pharmaceutical API exports are showing signs of recovery as regional shipping conditions improve. Buyers dependent on antibiotic APIs should use July to verify logistics, rebuild inventories and secure Q3 supply agreements. This guide evaluates logistics recovery, procurement risks and outlines actionable Q3 sourcing strategies.
OCP Morocco’s TSP Cargoes Ease India’s Fertilizer Shortage
India’s tight fertilizer market finds relief as OCP Morocco dispatches triple superphosphate (TSP) shipments, replenishing stocks and supporting crop plans. Yet, global supply constraints keep the market volatile. The article explores the impact of these cargoes and future outlook.
FACT Ammonia Tender 2026: Formula Pricing Sets New Procurement Standard
FACT India’s new 2026 ammonia tender marks a decisive move toward formula‑linked contracts, offering stability in a market plagued by volatile fertilizer prices. This long‑duration deal signals a strategic shift in fertilizer procurement, providing a predictable pricing framework for the next decade.
Pharmaceutical Supply Chain: H1 2026 Closing Risk Assessment
The first half of 2026 exposed major vulnerabilities in pharmaceutical supply chains. API concentration, shipping disruptions, and logistics risks are reshaping procurement strategies for H2 2026 and beyond.
Don't miss out on our updates! Subscribe to our newsletter now
We're committed to your privacy. Tradeasia uses the information you provide to us to contact you about our relevant content, products, and services. For more information, check out our privacy policy.